APEI — American Public Education, Inc. · 2026-09-05 · Verdict: WATCH · Conviction 3

Price $45.36 (screen row in universe_under2b.csv, file dated 2026-09-05; no live quotes in sandbox) · Mkt cap ~$833M (18.37M shares) · EV ~$697M · EV/EBIT (FY25 actual) 14.5x · EV/adj EBITDA (FY26 guided mid) ~7.0x · Owner FCF yield ~6% on cap · Net cash $135.5M · ADV $13.6M Sources read: 10-K filed 2026-03-12 (Items 1, 1A, 7), 10-Q filed 2026-08-10, DEF 14A filed 2026-04-09, 8-Ks 2026-03-12, 2026-05-11, 2026-08-05, 2026-08-10, Form 4s (trailing 12m), triage note 2026-09-04. No transcript in the bundle.

1. What the business actually does

APEI educates about 109,000 students through one institution, American Public University System (10-Q 2026Q2, Overview). Military+ (formerly APUS) teaches roughly 89,400 online adult learners, 62% of whom self-reported active-duty service at first enrollment. Health+ (formerly Rasmussen University and Hondros) teaches about 19,600 nursing and health-sciences students at 27 campuses in eight states plus online, split 11,100 on-ground and 8,500 online (10-Q, Overview). The money comes from the federal government. At APUS in 2025, DoD Tuition Assistance was 41% of revenue, VA benefits 26%, Title IV 19%, and cash and other sources 14%; at Rasmussen, Title IV was 78% and cash 20% (10-K 2025, Item 1).

2. Why it is mispriced: the edge case

The triage framing was "misunderstood segment": Military+ earned $23.7M of operating income on $85.5M of revenue in Q2 (28% margin) while Health+ earned $0.3M on $86.2M, so Health+ and its ~$344M revenue base look free (8-K 2026-08-10, segment summary). That framing does not survive the corporate line. Corporate and Other cost $46.1M in 2025 and $20.1M in H1 2026 (10-K Item 7; 10-Q segment table). Charge even half of it to Military+ and the "free option" disappears.

The better edge case is regulatory, and it closed on August 4. APUS's 90/10 ratio was 89% for 2025 against a 90% ceiling, with a second consecutive failure meaning loss of Title IV and, because DoD requires Title IV participation, loss of TA as well (10-K Item 1A, "If one or more of our institutions does not comply with the 90/10 Rule"). Rasmussen has run under 80% for three years, and management said plainly that the Combination "is expected to benefit 90/10 Rule compliance" (same risk factor). On August 4-5, 2026, ED approved and the company completed the Institutional Combination into a single HLC-accredited institution (8-K 2026-08-05). Blending an 89% institution with a sub-80% institution of similar revenue defuses the one genuinely existential risk here. Who is indifferent: an 18.4M-share company at $13.6M ADV, where the resolution arrived as a Reg FD 8-K three business days before earnings rather than as a headline.

3. Unit economics and growth

FY2025 revenue was $648.9M, up 3.9%, with EBIT of $47.9M and adjusted EBITDA of $85.7M against $72.3M in 2024 (10-K Item 7; DEF 14A Annex B). H1 2026 revenue was $346.5M, up 5.9%, with operating margin at 10.2% versus 5.9% (10-Q, Summary of Results). Military+ H1 operating income was $54.4M on $175.0M, a 31.1% margin, on 3.0% registration growth; Health+ turned $0.8M of operating income on $171.6M against a $3.2M loss, on 7.0% enrollment growth (10-Q, segment analysis). Bad debt is creeping: 3.5% of revenue in H1 2026 versus 3.0% (10-Q, G&A).

The deceleration in the guide is the number that matters. Q3 guidance calls for Military+ registrations up 1.0-3.0% and Health+ enrollment of 19,100, up 2.5%, against Q2 actuals of +2.0% and +6.6% (8-K 2026-08-10, outlook). Q3 adjusted EBITDA is guided to $14.0-17.0M against $20.7M last year. Since H1 delivered $49.9M, the raised full-year range of $96-104M requires a Q4 of roughly $32-37M against an implied $28.7M in Q4 2025. That is the entire raise, sitting in one quarter.

4. Balance sheet and capital allocation

Cash, restricted cash and short-term investments were $222.8M at June 30 against $87.3M of total debt, so net cash is about $135.5M, or 16% of the market cap (8-K 2026-08-10, balance sheet). The March 2026 PNC facility ($90M term loan, $40M revolver) carries a 2.50x net leverage covenant, a 2.50x interest coverage covenant and a $40M minimum unrestricted cash test; net leverage was negative 0.11 at June 30 (10-Q, Liquidity). Capital allocation is the weak spot. A $50M buyback was authorized on March 10, 2026, and only $5M had been used by June 30 (10-Q, Share Repurchase); shares outstanding still rose from 18,125,860 to 18,367,887 over the half, so repurchases have not offset grant dilution. Insiders are net sellers: zero open-market purchases and 20,113 shares sold for $979,333 in the trailing twelve months, including the APUS president exercising and selling 8,800 shares on 2026-08-12 (form4_summary.md; form4_last12m.csv). CEO Selden holds 2.5% and directors and officers 10.6%, most of that being activist 325 Capital's 6.6% board stake (DEF 14A, beneficial ownership).

5. Management: said versus did

They have beaten their own bar three times running. FY26 adjusted EBITDA guidance went from $91.5-100.5M in March to $93-102M in May to $96-104M in August (8-Ks 2026-03-12, 2026-05-11, 2026-08-10). Q1 adjusted EBITDA came in at $29.2M against a $25.5-27.0M guide and Q2 at $20.7M against $16.5-18.0M. Revenue landed inside the guided range both quarters, and Q2 registrations landed at the low end of the 98,300-100,300 guide, so the beats are cost and mix, not demand upside.

6. Valuation

At $45.36 and $697M of EV, the stock trades at roughly 7.0x guided FY26 adjusted EBITDA of $100M and 17x guided EPS of $2.48-2.79. Normalized owner earnings are thinner than the EBITDA suggests: $100M less about $26.5M of guided capex, about $16M of cash tax and $8.9M of stock compensation leaves roughly $50M, a 6% yield on the cap.

Base (50%): no appropriations lapse, FY26 lands at $100M and FY27 at $107M on 5% revenue growth and Health+ margin near 3%; 7.5x gives $52 a share, up 15%. Bear (30%): October 2026 appropriations lapse repeats the 20,600-registration Q4 hit (10-K Item 7, U.S. Federal Government Shutdown), FY27 adjusted EBITDA falls to $85M and the multiple compresses to 5.5x; $32.50 a share, down 28%. Bull (20%): Health+ reaches a 7% operating margin on $390M by FY28 while Military+ holds $107M and corporate stays near $40M, giving roughly $122M of adjusted EBITDA at 8x plus accumulated cash; $68 a share, up 50%. Probability-weighted value is about $49, roughly 9% above the price.

Reverse DCF: the current EV of $697M against roughly $50M of maintainable owner FCF implies a 7.2% perpetual return at zero growth, or a 10% return on about 2.5% perpetual FCF growth. The price already assumes federal funding continuity and modest compounding. There is no discount for a shutdown.

7. Catalysts and timeline

Federal FY2027 appropriations on or about October 1, 2026 is the binary. Q3 results in early November test the deceleration; Q4 and FY26 results in March 2027 test the raise. Illinois IDFPR action on Rasmussen's ADN program, which the regulator has publicly reported missed the required NCLEX pass rate for six straight years, follows the September 2026 expiry of the probation moratorium (10-Q, State Authorization). ED's APUS program review, open since July 2023 and covering 90/10 compliance, remains unreported (10-K Item 1A). Post-Combination cost consolidation and the unused $45M buyback are the self-help levers.

8. Risks and pre-registered kill criteria

The company's fate is set by payors it does not control. Kill the thesis if any of these is observed: 1. Military+ net course registrations decline year over year in any reported quarter. 2. The System's reported 90/10 percentage exceeds 90% for fiscal 2026 in the FY26 10-K, or ED's program review report imposes a liability, growth restriction or provisional condition on APUS. 3. Health+ segment operating margin fails to exceed 2% in two consecutive quarters through Q2 2027. 4. FY26 adjusted EBITDA comes in below $92M, that is, below the original March guidance floor, making the two raises unearned.

9. Verdict and one-paragraph summary

WATCH, conviction 3. American Public Education just removed the risk that could have zeroed it: the August 4 Institutional Combination folds an APUS that was running at 89% of a hard 90% federal-funding ceiling into one accredited institution with Rasmussen, which has run under 80%, and management has said in writing the Combination should help 90/10 compliance. Underneath that, both segments are growing, operating margin has gone from 5.9% to 10.2% in a year, the balance sheet holds $135M of net cash, and the stock trades at about 7x guided FY26 adjusted EBITDA. What stops this being an idea today is that the cheapness is not extreme once you charge the $40M-plus corporate cost against the profitable Military+ segment, the stock has already re-rated (up 60% over twelve months and only 25% off its high), the raised full-year guidance parks essentially all its upside in a Q4 that is exposed to exactly the appropriations lapse that cost APUS 20,600 registrations in last year's Q4, and Health+ enrollment growth is guided to fall from 6.6% to 2.5%. Insiders sold roughly $1M and bought nothing. Wait for October appropriations to clear and for Q3 to show Health+ growth is not rolling over, and this becomes a real idea.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.